Pier F. Conte

Venice, 30126, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Speech-Language Pathology-Related Disorders in Adults with Brain Tumours: A Narrative Review.

Speech-Language Pathology-Related Disorders in Adults with Brain Tumours: A Narrative Review.

Journal: Biomedicines

Published: June 23, 2026

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Journal: British journal of cancer

Published: February 24, 2022

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.

Journal: The oncologist

Published: June 24, 2021

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer.

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer.

Journal: Translational lung cancer research

Published: November 19, 2020

Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy.

Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy.

Journal: JCO oncology practice

Published: December 20, 2019

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.

Journal: Cancer treatment reviews

Published: October 02, 2019

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Journal: BMC cancer

Published: June 13, 2019

Corrigendum to "Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?" [Crit. Rev. Oncol. Hematol. 138 (June) (2019), 87-103].

Corrigendum to "Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?" [Crit. Rev. Oncol. Hematol. 138 (June) (2019), 87-103].

Journal: Critical reviews in oncology/hematology

Published: June 10, 2019

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Journal: BMC cancer

Published: June 06, 2018

Showing 1-9 of 9

Last Updated: 09/26/2026